Last updated: February 15, 2026
What Is the Current Market Status of NDC 45802-0717?
NDC 45802-0717 is associated with Repatha (evolocumab), a PCSK9 inhibitor designed to lower LDL cholesterol levels. Repatha is approved for reducing cardiovascular risk in patients with atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia. As of 2023, the drug generates approximately $1.8 billion annually, with sales expanding primarily in the United States, Europe, and select Asian markets. Its market share among lipid-lowering therapies continues to grow but faces competitive pressure from other novel agents.
How Is the Market for PCSK9 Inhibitors Evolving?
Market size: Valued at around $4.5 billion in 2022, driven by increased diagnosis of hypercholesterolemia and greater adoption of PCSK9 inhibitors.
Market growth rate: Projected CAGR of 9% from 2022 to 2027, fueled by expanded indications and patient population.
Key competitors: Incline with Repatha are Praluent (alirocumab), which holds about 30% market share, and emerging therapies such as inclisiran (by Novartis), which may alter the landscape.
Reimbursement landscape: Insurance coverage has improved, with several formularies favoring PCSK9 inhibitors for specific high-risk populations. Patent protections and pricing negotiations influence market penetration.
What Are the Price Trends for Repatha (NDC 45802-0717)?
Current list price: Approximate annual list price of $6,600 per patient, with variations based on pharmacy discounts and insurance arrangements.
Pricing dynamics: Repatha’s pricing has remained relatively stable since launch in 2015. Negotiations with payers and risk-sharing agreements have moderated net prices for some providers.
Comparative pricing: Praluent list price hovers near $6,500 annually. Inclisiran, entering the market with lower administered costs, presents price competition but is yet to capture significant market share in the U.S.
Pricing pressures: The high cost of PCSK9 inhibitors is under scrutiny due to payers' cost containment efforts and value-based pricing models. Initiatives to lower costs could influence future list prices.
What Are the Implications of Patent Expirations and Biosimilar Entry?
Patent expiration: The primary patent for Repatha is slated for 2030 in the U.S., with patent extensions possible based on patent linkage and regulatory exclusivity.
Biosimilar development: As of 2023, no biosimilar versions have entered the market. The complexity of biosimilar approval for monoclonal antibodies like evolocumab delays generic competition.
Market impact: Patent expiry could precipitate price reductions of 30-50%, depending on biosimilar uptake and payer negotiations.
What Are Future Price Projections and Market Size Opportunities?
Projected price trends: Historically, prices have remained stable; however, due to increased competition and payer pressure, prices are expected to decline by 10-20% over the next five years.
Market growth: Adjacent indications, including expanded use in pediatric populations and primary prevention in high-risk patients, may increase overall market size by approximately 20% by 2028.
Pricing strategies: Manufacturers may adopt tiered pricing, risk-sharing agreements, and discounts to sustain market penetration amid increasing competition and cost containment strategies.
Key Takeaways
- Repatha remains a leading LDL-lowering agent with a market value near $1.8 billion annually.
- Market growth is driven by higher cardiovascular risk management adoption and expanded indications.
- The current list price of approximately $6,600 per year has remained stable but faces future downward pressures.
- Patent protections and biosimilar entry are key factors influencing potential price reductions starting around 2030.
- Competitive landscape shifts, including emerging therapies like inclisiran, may influence future market share and pricing.
FAQs
1. When is Repatha’s patent expiration expected?
Patents are scheduled to expire in 2030, with some extensions possible depending on legal and regulatory factors.
2. How does Repatha compare to Praluent in price?
Both drugs have similar list prices, approximately $6,500 to $6,600 annually. Price negotiations can slightly vary based on payers.
3. What is the outlook for biosimilar entry?
No biosimilars are approved as of 2023. Development is ongoing, but complexity of biologics delays market entry.
4. How are payer policies affecting Repatha’s market?
Insurance coverage has expanded, with payers favoring high-risk patients. Cost-sharing and prior authorization inquiries influence patient access.
5. What factors could reduce Repatha's price in the future?
Patent expiration, biosimilar entry, increased competition, and payer pressure could lower prices by as much as 50% over the next decade.
Citations:
- Evaluate Pharma, "Lipid-Lowering Agents Market Analysis," 2023.
- IQVIA Sales Data, "Repatha Revenue and Market Share," 2023.
- FDA, "Repatha Approval and Patent Status," 2022.
- Health Economics Review, "Cost-Containment Strategies for PCSK9 Inhibitors," 2022.
- Novartis Press Release, "Inclisiran Market Entry," 2023.
